MKI67 and neoplasm: Recently, Demura et al. (2017), reported lower Ki-67 expression in those patients treated with selective progesterone receptor modulators (SPRMs) whose tumor volume significantly decreased, and claimed it was an antiproliferative and a proapoptotic effect of the treatment [32].